– EXPAND-1 is a clinical study with ANV600, a novel PD-1 targeted IL-2R-βγ agonist, in monotherapy and in combination with pembrolizumab in cancer patients –

Basel, May 21, 2025 – Anaveon, a clinical stage, immuno-oncology company, today announced that it will present a poster on ANV600 at the American Society for Clinical Oncology (ASCO) Annual Meeting being held from Friday, May 30, 2025 to Tuesday, June 3, 2025 in Chicago, Illinois.

“ANV600 is a novel, powerful PD-1 targeted therapeutic which expands PD-1+ T cells in the tumor microenvironment and is combinable with PD-1 inhibitors used in clinical practice,” said Richard Sachse, Chief Medical Officer at Anaveon. “We will broadly explore this molecule in clinical studies to determine its full therapeutic potential in patients.”

Posters will be available on the virtual meeting platform and at anaveon.com beginning 7:00 a.m. CST on June 2, 2025.

Details of the poster presentation:
Monday, June 2, 2025, 1:30-4:30 p.m. CST

Poster #TPS2701 (download poster TPS2701 here)

Title: EXPAND-1, a Phase I/II study with ANV600, a novel PD-1 targeted IL-2R-βγ agonist, in monotherapy and in combination with pembrolizumab, in patients with advanced solid tumors

Authors: I. Korakis, M. Imbimbo, E. Calvo, S. Ochsenreither, I. Ortego Zabalza, P. Tomasini, K. Ouali, A. Desuki, D. Di Blasi, E. Gasal and M. Joerger

Anaveon’s mission is to harness the power of the immune system for life-changing treatments. The company was founded in 2017 by scientists and industry experts, who aspire to invent and develop therapeutic treatments that benefit patients and society. Today, Anaveon is a clinical stage biopharmaceutical company that specializes in developing novel treatments for diseases with high unmet needs. Our team is driven to make this vision a reality: we are committed to transforming immunological insights into life-changing therapies.

ENDS

Media contact:
Benz Advisory
Beatrix Benz
Email:  beatrix.benz@benz-advisory.com
Tel: +41 79 256 77 73

About Anaveon:
Anaveon is an international biotechnology company located in Basel, Switzerland. Using our immunological knowledge and expertise in protein engineering, we develop medicines to deliver meaningful benefits to cancer patients. Our lead compound ANV600 is currently in clinical trials in solid tumors.

Find out more at  anaveon.com